Cargando…

Late radiation toxicity in Hodgkin lymphoma patients: proton therapy's potential

In 2010, all young patients treated for intrathoracic Hodgkin lymphoma (HL) at one of 10 radiotherapy centers in the province of Quebec received 3D conformal photon therapy. These patients may now be at risk for late effects of their treatment, notably secondary malignancies and cardiac toxicity. We...

Descripción completa

Detalles Bibliográficos
Autores principales: Toltz, Allison, Shin, Naomi, Mitrou, Ellis, Laude, Cecile, Freeman, Carolyn R., Seuntjens, Jan, Parker, William, Roberge, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5690189/
https://www.ncbi.nlm.nih.gov/pubmed/26699298
http://dx.doi.org/10.1120/jacmp.v16i5.5386
_version_ 1783279551568150528
author Toltz, Allison
Shin, Naomi
Mitrou, Ellis
Laude, Cecile
Freeman, Carolyn R.
Seuntjens, Jan
Parker, William
Roberge, David
author_facet Toltz, Allison
Shin, Naomi
Mitrou, Ellis
Laude, Cecile
Freeman, Carolyn R.
Seuntjens, Jan
Parker, William
Roberge, David
author_sort Toltz, Allison
collection PubMed
description In 2010, all young patients treated for intrathoracic Hodgkin lymphoma (HL) at one of 10 radiotherapy centers in the province of Quebec received 3D conformal photon therapy. These patients may now be at risk for late effects of their treatment, notably secondary malignancies and cardiac toxicity. We hypothesized that more complex radiotherapy, including intensity‐modulated proton therapy (IMPT) and possibly IMRT (in the form of helical tomotherapy (HT)), could benefit these patients. With institutional review board approval at 10 institutions, all treatment plans for patients under the age of 30 treated for HL during a six‐month consecutive period of 2010 were retrieved. Twenty‐six patients were identified, and after excluding patients with extrathoracic radiation or treatment of recurrence, 20 patients were replanned for HT and IMPT. Neutron dose for IMPT plans was estimated from published measurements. The relative seriality model was used to predict excess risk of cardiac mortality. A modified linear quadratic model was used to predict the excess absolute risk for induction of lung cancer and, in female patients, breast cancer. Model parameters were derived from published data. Predicted risk for cardiac mortality was similar among the three treatment techniques (absolute excess risk of cardiac mortality was not reduced for HT or IMPT ([Formula: see text]) as compared to 3D CRT). Predicted risks were increased for HT and reduced for IMPT for secondary lung cancer ([Formula: see text]) and breast cancers ([Formula: see text]) as compared to 3D CRT. PACS numbers: 87.55.dh, 87.55.dk
format Online
Article
Text
id pubmed-5690189
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-56901892018-04-02 Late radiation toxicity in Hodgkin lymphoma patients: proton therapy's potential Toltz, Allison Shin, Naomi Mitrou, Ellis Laude, Cecile Freeman, Carolyn R. Seuntjens, Jan Parker, William Roberge, David J Appl Clin Med Phys Radiation Oncology Physics In 2010, all young patients treated for intrathoracic Hodgkin lymphoma (HL) at one of 10 radiotherapy centers in the province of Quebec received 3D conformal photon therapy. These patients may now be at risk for late effects of their treatment, notably secondary malignancies and cardiac toxicity. We hypothesized that more complex radiotherapy, including intensity‐modulated proton therapy (IMPT) and possibly IMRT (in the form of helical tomotherapy (HT)), could benefit these patients. With institutional review board approval at 10 institutions, all treatment plans for patients under the age of 30 treated for HL during a six‐month consecutive period of 2010 were retrieved. Twenty‐six patients were identified, and after excluding patients with extrathoracic radiation or treatment of recurrence, 20 patients were replanned for HT and IMPT. Neutron dose for IMPT plans was estimated from published measurements. The relative seriality model was used to predict excess risk of cardiac mortality. A modified linear quadratic model was used to predict the excess absolute risk for induction of lung cancer and, in female patients, breast cancer. Model parameters were derived from published data. Predicted risk for cardiac mortality was similar among the three treatment techniques (absolute excess risk of cardiac mortality was not reduced for HT or IMPT ([Formula: see text]) as compared to 3D CRT). Predicted risks were increased for HT and reduced for IMPT for secondary lung cancer ([Formula: see text]) and breast cancers ([Formula: see text]) as compared to 3D CRT. PACS numbers: 87.55.dh, 87.55.dk John Wiley and Sons Inc. 2015-09-08 /pmc/articles/PMC5690189/ /pubmed/26699298 http://dx.doi.org/10.1120/jacmp.v16i5.5386 Text en © 2015 The Authors. This is an open access article under the terms of the Creative Commons Attribution (http://creativecommons.org/licenses/by/3.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Radiation Oncology Physics
Toltz, Allison
Shin, Naomi
Mitrou, Ellis
Laude, Cecile
Freeman, Carolyn R.
Seuntjens, Jan
Parker, William
Roberge, David
Late radiation toxicity in Hodgkin lymphoma patients: proton therapy's potential
title Late radiation toxicity in Hodgkin lymphoma patients: proton therapy's potential
title_full Late radiation toxicity in Hodgkin lymphoma patients: proton therapy's potential
title_fullStr Late radiation toxicity in Hodgkin lymphoma patients: proton therapy's potential
title_full_unstemmed Late radiation toxicity in Hodgkin lymphoma patients: proton therapy's potential
title_short Late radiation toxicity in Hodgkin lymphoma patients: proton therapy's potential
title_sort late radiation toxicity in hodgkin lymphoma patients: proton therapy's potential
topic Radiation Oncology Physics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5690189/
https://www.ncbi.nlm.nih.gov/pubmed/26699298
http://dx.doi.org/10.1120/jacmp.v16i5.5386
work_keys_str_mv AT toltzallison lateradiationtoxicityinhodgkinlymphomapatientsprotontherapyspotential
AT shinnaomi lateradiationtoxicityinhodgkinlymphomapatientsprotontherapyspotential
AT mitrouellis lateradiationtoxicityinhodgkinlymphomapatientsprotontherapyspotential
AT laudececile lateradiationtoxicityinhodgkinlymphomapatientsprotontherapyspotential
AT freemancarolynr lateradiationtoxicityinhodgkinlymphomapatientsprotontherapyspotential
AT seuntjensjan lateradiationtoxicityinhodgkinlymphomapatientsprotontherapyspotential
AT parkerwilliam lateradiationtoxicityinhodgkinlymphomapatientsprotontherapyspotential
AT robergedavid lateradiationtoxicityinhodgkinlymphomapatientsprotontherapyspotential